- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01858870
Observational Retrospective Study of Effectivity and Tolerability in Patients With Lacosamide Medication
Lacosamide is an antiepileptic drug approved for using like adjuvant treatment in adults epileptic crisis.
Previous studies has granted to the adjuvant therapy a significant efficacy. This is an observational study, multicenter and retrospective, in patients with epilepsy. The aim of study is the evaluation of the adjuvant treatment with Lacosamide administered over 12 months.
The investigators will collect information from 860 patients in 13 spanish centers.
The secondary aim is assess the tolerability of treatment during 3,6 and 12 month.
Study Overview
Detailed Description
During the treatment we will performed a analysis in three different times (3, 6 and 12 month)for obtain a vision of tolerability and efficacy for Lacosamide in usual clinical practice. We intended describe the differences when we add Lacosamide to an antiepileptic drug, sodium channel blocker or no-sodium channel blocker in usual clinical practice.
Clinical data obtained through post-hoc analysis for registered pivotal studies made in highly refractory epileptic patients show that adjuvant treatment with Lacosamide has an extra efficacy compared with placebo. It is self-depended to the treatment with or without sodium channel blockers.
This study will allow us to obtain information about real existing most population where do not exist as high refractoriness as the pivotal studies.
The population of study is:
Patients with epilepsy, with plus that 18 years old patients, with initial partial crisis treated with Lacosamide according to usual clinical practice in Spain.
Lacosamide must has been used for epilepsy treatment at least during 12 month.
The data record is collection in 5 months.
Inclusion criteria:
- Adults (+18).
- Patients with epilepsy partial crisis diagnostic that had been treated with Lacosamide according to usual clinical practice.
- The patient had at least one partial crisis during the year before to the initiation of treatment with Lacosamide.
- The patient or their legal agent is reliable and is be able to adhere to the protocol according to the investigation criteria.
Exclusion criteria:
- Patient is in an other study of medical protocol or medical implant.
- Patients with other kind of epilepsy.
- patients with chronic alcoholism or abuse drug recording in the last year.
- patients who don't be in possession of their faculties in the moment to sign Informed Consent.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Valencia, Spain, 46026
- Iis la Fe
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- The patient, male or female, over 18 years.
- The patient has a diagnosis of prostate cancer of any kind, and has been treated with Lacosamide according to routine clinical practice.
- The patient had at least one Partial Crisis during the year prior to initiation of treatment with Lacosamide.
- The patient or their legal representative is reliable and able to adhere to the protocol (ie, is able to understand and complete the interview at the study visit), at the discretion of the investigator.
Exclusion Criteria:
- Patient is participating in another study of a medicinal product research (PMI) or a medical implant.
- Patients with other types of epilepsy.
- Patients with a history of chronic alcoholism or drug abuse in the last year.
- Patients who are not in possession of his faculties at the time of obtaining the Informed Consent.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Lacosamide
patients with Partial Crisis of epilepsy treated with Lacosamide for at least 12 months
|
routine clinical practice
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The percentage of responders (patients with a crisis reduction of> 50%) at 12 months of treatment.
Time Frame: twelve months
|
The primary objective of the study is to assess the efficacy of through in patients with Partial Crisis, with a minimum duration of 12 months.
|
twelve months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients reporting Adverse Events spontaneously potentially caused by the drug.
Time Frame: twelve months
|
The secondary objective is to assess the tolerability of treatment with through in patients with Partial Crisis at 3, 6 and 12 months.
|
twelve months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Vicente V Villanueva, doctor, Iis la Fe
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LACO-EXP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Neuroelectrics CorporationRecruitingEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
University Hospital, LilleUnknownFocal Epilepsy | Epilepsy IntractableFrance
-
Xuanwu Hospital, BeijingPeking University; Beijing Tiantan Hospital; Qilu Hospital of Shandong University and other collaboratorsNot yet recruitingEpilepsy, Drug ResistantChina
Clinical Trials on lacosamide
-
Seoul National University HospitalDongsan Medical Center; Konkuk UniversityCompleted
-
University of California, San FranciscoSan Francisco VA Health Care SystemCompletedAlcohol Use DisorderUnited States
-
UCB Biopharma S.P.R.L.Completed
-
UCB Biopharma S.P.R.L.CompletedHealthy VolunteersUnited Kingdom
-
UCB PharmaCompleted
-
UCB Pharma SAUCB Japan Co. Ltd.CompletedEpilepsy | Partial Onset SeizuresChina, Japan
-
UCB Pharma SACompletedHealthy VolunteersUnited Kingdom
-
Overseas Pharmaceuticals, Ltd.Beijing Capton Pharmaceutical Technology Development Co., LTDNot yet recruiting
-
UCB BIOSCIENCES, Inc.CompletedEpilepsyUnited States, Australia, Brazil, Bulgaria, China, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Taiwan
-
UCB Biopharma S.P.R.L.CompletedHealthy Male Chinese VolunteersChina